Rofecoxib associated with diaphragm disease.
作者信息
Lapner Michael A, Stephen Wesley J
机构信息
Department of Surgery, McMaster University, Hamilton, ON, Canada.
出版信息
Can J Surg. 2007 Dec;50(6):E27-8.
Abstract
摘要
相似文献
1
Rofecoxib associated with diaphragm disease.罗非昔布与膈疾病相关。
Can J Surg. 2007 Dec;50(6):E27-8.
2
The Vioxx fallout.万络事件的影响。
Minn Med. 2005 Mar;88(3):26-30.
3
[Rofecoxib increases myocardial infarction risk in seniors].[罗非昔布增加老年人心肌梗死风险]
Med Monatsschr Pharm. 2005 Nov;28(11):416-7.
4
Adverse cardiovascular effects of rofecoxib.罗非昔布的心血管不良反应。
N Engl J Med. 2006 Jul 13;355(2):204; author reply 204-5.
5
Adverse cardiovascular effects of rofecoxib.罗非昔布的心血管不良影响。
N Engl J Med. 2006 Jul 13;355(2):203-4; author reply 203-5. doi: 10.1056/NEJMc066260. Epub 2006 Jun 26.
6
The NSAID roller coaster: more about rofecoxib.非甾体抗炎药的过山车：更多关于罗非昔布的内容。
Br J Clin Pharmacol. 2006 Sep;62(3):257-9. doi: 10.1111/j.1365-2125.2006.02761.x.
7
Rofecoxib and clinically significant gastrointestinal events.罗非昔布与具有临床意义的胃肠道事件
Am J Med Sci. 2011 Nov;342(5):438-9. doi: 10.1097/MAJ.0b013e31822f3ff4.
8
Court awards claimant 13.5m dollars in rofecoxib lawsuit.
BMJ. 2006 Apr 22;332(7547):927. doi: 10.1136/bmj.332.7547.927-a.
9
Withdrawal of rofecoxib - a wake up call for drug safety.
Kathmandu Univ Med J (KUMJ). 2004 Oct-Dec;2(4):360.
10
94% of patients suing Merck over rofecoxib agree to company's offer.因罗非昔布起诉默克公司的患者中，94%同意了该公司的提议。
BMJ. 2008 Mar 15;336(7644):580-1. doi: 10.1136/bmj.39513.541296.DB.
引用本文的文献
1
Clinical Features, Diagnosis, and Treatment Strategies of Gastrointestinal Diaphragm Disease Associated with Nonsteroidal Anti-Inflammatory Drugs.非甾体抗炎药相关的胃肠道隔膜病的临床特征、诊断及治疗策略
Gastroenterol Res Pract. 2016;2016:3679741. doi: 10.1155/2016/3679741. Epub 2016 Mar 28.
2
Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety.短半衰期非甾体抗炎药长期暴露对胃肠道安全性的影响。
Inflammopharmacology. 2009 Aug;17(4):205-10. doi: 10.1007/s10787-009-0007-y. Epub 2009 Jul 8.
本文引用的文献
1
NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.非甾体抗炎药引起的胃肠道损伤：当前的临床管理及预防建议
Chin J Dig Dis. 2006;7(3):127-33. doi: 10.1111/j.1443-9573.2006.00257.x.
2
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.一项结直肠腺瘤化学预防试验中与罗非昔布相关的心血管事件。
N Engl J Med. 2005 Mar 17;352(11):1092-102. doi: 10.1056/NEJMoa050493. Epub 2005 Feb 15.
3
Cyclooxygenase 2 selective inhibitor induced bowel stricture: a case report.环氧化酶-2选择性抑制剂诱发肠狭窄：一例报告
Gut. 2004 Jan;53(1):154. doi: 10.1136/gut.53.1.154.
4
COX-2 inhibitors.环氧化酶-2抑制剂
Lancet. 1999 Jan 23;353(9149):307-14. doi: 10.1016/s0140-6736(98)12154-2.
5
Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy.一名长期接受吲哚美辛治疗的患者出现空肠溃疡和狭窄。
Am J Gastroenterol. 1973 Feb;59(2):162-9.
6
Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs.膈膜病：非甾体抗炎药所致小肠疾病的病理学
J Clin Pathol. 1988 May;41(5):516-26. doi: 10.1136/jcp.41.5.516.
Zotero 插件